Oscar Health Stock Analysis: Buy or Sell?
Summary
Parkev provides a comprehensive analysis of Oscar Health, highlighting the company's transition from significant losses to improving profitability. Parkev notes that the business has grown its revenue from approximately $1 billion in 2021 to over $15 billion in the trailing 12-month period, supported by a 46% year-over-year increase in membership to nearly 3 million users. A key driver of this success is Parkev's observation of the company's use of AI to automate claims, which has helped swing operating profit margins from -90% in 2021 to a positive 4.11%.
Parkev emphasizes that the company's return on invested capital (ROIC) stands at an impressive 30%, which far exceeds its cost of capital. While Oscar Health is trading at a forward P/E ratio of 16.1—the higher end of its historical range—Parkev argues this is justified by the robust fundamental data. Parkev revised his discounted cash flow model upward due to better-than-expected top-line growth and efficiency gains, resulting in a calculated fair value of $49.90 per share, significantly above the current market price of approximately $30.80.
Mentioned Stocks
Reasoning: Parkev reiterated a buy recommendation for Oscar Health, citing strong membership growth of 46% and a dramatic improvement in operating profit margins from -90% to over 4%. Parkev calculates a fair value of $49.90 per share using a discounted cash flow model, which is significantly higher than the current market price of $30.80. Although Parkev notes a low conviction level due to the company's short history since 2021, the 30% return on invested capital and AI-driven efficiency gains make the stock look undervalued even near its 52-week high.